Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Receivables (2017 - 2025)

Historic Change in Receivables for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $7.4 million.

  • Puma Biotechnology's Change in Receivables fell 7190.64% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.8 million, marking a year-over-year decrease of 18426.78%. This contributed to the annual value of -$16.3 million for FY2024, which is 29532.74% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Change in Receivables is $7.4 million, which was down 7190.64% from $376000.0 recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Change in Receivables registered a high of $26.5 million during Q3 2024, and its lowest value of -$23.1 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Receivables was $615000.0 (2021), whereas its average is $369578.9.
  • In the last 5 years, Puma Biotechnology's Change in Receivables soared by 156919.19% in 2021 and then plummeted by 99219.51% in 2022.
  • Quarter analysis of 5 years shows Puma Biotechnology's Change in Receivables stood at $8.7 million in 2021, then surged by 41.17% to $12.3 million in 2022, then surged by 56.09% to $19.2 million in 2023, then tumbled by 219.76% to -$23.0 million in 2024, then skyrocketed by 132.31% to $7.4 million in 2025.
  • Its Change in Receivables stands at $7.4 million for Q3 2025, versus $376000.0 for Q2 2025 and -$6.6 million for Q1 2025.